Treatment
Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression
Cells 2025 October 15 [Link] Luca Hegedüs, Silvia Qaisieh, Christian Stülpnagel, Yavar Ganjeh Khor Dezfouli, Winny Tambo, Fabian Doerr, Natalie Baldes, Dirk Theegarten, Martin Schuler, Servet Bölükbas, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare cancer that often develops after a decades-long latency period and confers a grim prognosis. Novel, biomarker-based therapeutic modalities…
Read MorePD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma
Translational Lung Cancer Research 2025 September 30 [Link] Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka Abstract Background: Pleural mesothelioma (PM) is an uncommon malignancy with a poor prognosis, even after surgical resection. Programmed death-ligand 1 (PD-L1) expression is a potential prognostic biomarker in various…
Read MoreComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
Clinical Medicine Insights Oncology 2025 October 17 [Link] Doğan Bayram, Safa Can Efil, Serap Türk, Oğuz Kara, Serhat Sekmek, Şebnem Yücel, Selin Aktürk Esen, Gökhan Uçar, Oznur Bal, Efnan Algin, Doğan Uncu Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with…
Read MoreComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
Clinical Medicine Insights Oncology 2025 October 17 [Link] Doğan Bayram, Safa Can Efil, Serap Türk, Oğuz Kara, Serhat Sekmek, Şebnem Yücel, Selin Aktürk Esen, Gökhan Uçar, Oznur Bal, Efnan Algin, Doğan Uncu Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with…
Read MoreFL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination
Journal of Experimental Clinical Cancer Research 2025 October 21 [Link] Ieman A M Aljahdali, Xiang Ling, Wenjie Wu, Wenchao Wang, Dan Li, Renyuan Zhang, Emma Zhang, Aimee Stablewski, Rami Azrak, Qingyong Li, Fengzhi Li Abstract Background: Malignant pleural mesothelioma (MPM) responds poorly to chemotherapy and is a highly progressive malignancy with a median survival time…
Read MoreResveratrol Affects Cell Activities, Induces Apoptosis and Regulates AMPK Signaling Pathway in Pleural Mesothelioma Cells
FASEB Journal 2025 October 31 [Link] Maria Rosa Iaquinta, Raffaella De Pace, Assia Benkhalqui, Cecilia Pesaresi, Simone Patergnani, Giulio Righes, Paolo Pinton, Mauro Tognon, Fernanda Martini, Elisa Mazzoni Abstract Pleural Mesothelioma (PM) is an aggressive tumor with a poor prognosis and limited therapeutic options. Despite the notion that resveratrol (RSV) significantly inhibits the growth of…
Read MoreA Rare Clinical Presentation of Malignant Pleural Mesothelioma With Central Nervous System Metastases: A Case Report
Cureus 2025 September 14 [Link] Magdalena A Miernik-Skrzypczak, Elwira Misztela-Lisiecka, Piotr Nowakowski, Anna Strozak, Grazyna Waska Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the pleural mesothelial cells, most often associated with long-term asbestos exposure. Symptoms are typically nonspecific, including shortness of breath, chest pain, and pleural effusion, which may…
Read MoreDiscovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma
Lung Cancer 2025 September 28 [Link] Jasper H L T van Genugten, Daniel Faulkner, Jens C Hahne, Charlotte Poile, Lodewyk Wessels, Dean A Fennell, Paul Baas Abstract Background: Malignant pleural mesothelioma (PM) is an aggressive cancer with limited treatment options. Although first-line nivolumab plus ipilimumab improves outcomes for some patients, a majority fail to respond.…
Read MoreFL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination
Journal of Experimental and Clinical Cancer Research 2025 October 21 [Link] Ieman A M Aljahdali, Xiang Ling, Wenjie Wu, Wenchao Wang, Dan Li, Renyuan Zhang, Emma Zhang, Aimee Stablewski, Rami Azrak, Qingyong Li, Fengzhi Li Abstract Background: Malignant pleural mesothelioma (MPM) responds poorly to chemotherapy and is a highly progressive malignancy with a median survival…
Read MoreGenetic variability of HIF1A and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma
Radiology and Oncology 2025 September 5 [Link] Matic Setina, Eva Setina, Ziga Doljak, Katja Goricar, Vita Dolzan, Viljem Kovac Abstract Background: Treatment of malignant mesothelioma (MM) still relies on chemotherapy with cisplatin in combination with pemetrexed or other drugs. Studies indicate that hypoxic conditions within tumour tissue may reduce responsiveness to cisplatin-based chemotherapy. Hypoxia-inducible factors…
Read More